UA72735C2 - Pharmaceutical composition for treatment of patients in intensive care units and method for its preparation - Google Patents

Pharmaceutical composition for treatment of patients in intensive care units and method for its preparation Download PDF

Info

Publication number: UA72735C2
Authority: UA; Ukraine
Prior art keywords: starch; sodium; molecular weight; pharmaceutical composition; solution
Prior art date: 1998-05-15

Application number

UA2000116454A

Other languages

English (en)

Ukrainian (uk)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-15

Filing date

1999-04-16

Publication date

2005-04-15

1999-04-16 Application filed filed Critical

2005-04-15 Publication of UA72735C2 publication Critical patent/UA72735C2/uk

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 21
238000000034 method Methods 0.000 title claims abstract description 19
238000011282 treatment Methods 0.000 title abstract description 13
238000002360 preparation method Methods 0.000 title description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 60
239000000203 mixture Substances 0.000 claims abstract description 45
229920002472 Starch Polymers 0.000 claims abstract description 31
239000011780 sodium chloride Substances 0.000 claims abstract description 31
239000008107 starch Substances 0.000 claims abstract description 31
235000019698 starch Nutrition 0.000 claims abstract description 31
235000002639 sodium chloride Nutrition 0.000 claims abstract description 27
108010010803 Gelatin Proteins 0.000 claims abstract description 13
229920000159 gelatin Polymers 0.000 claims abstract description 13
235000019322 gelatine Nutrition 0.000 claims abstract description 13
235000011852 gelatine desserts Nutrition 0.000 claims abstract description 13
239000008273 gelatin Substances 0.000 claims abstract description 12
239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 11
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 11
229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 11
239000000126 substance Substances 0.000 claims abstract description 11
229920002307 Dextran Polymers 0.000 claims abstract description 10
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims abstract description 7
229910001415 sodium ion Inorganic materials 0.000 claims abstract description 4
239000000243 solution Substances 0.000 claims description 46
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 20
239000008103 glucose Substances 0.000 claims description 20
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 19
229920001612 Hydroxyethyl starch Polymers 0.000 claims description 11
-1 ethylene epoxide Chemical class 0.000 claims description 11
229940050526 hydroxyethylstarch Drugs 0.000 claims description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 10
239000008215 water for injection Substances 0.000 claims description 10
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 8
239000001814 pectin Substances 0.000 claims description 8
235000010987 pectin Nutrition 0.000 claims description 8
229920001277 pectin Polymers 0.000 claims description 8
239000001632 sodium acetate Substances 0.000 claims description 8
235000017281 sodium acetate Nutrition 0.000 claims description 8
IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 claims description 7
238000002347 injection Methods 0.000 claims description 7
239000007924 injection Substances 0.000 claims description 7
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 6
239000000661 sodium alginate Substances 0.000 claims description 6
235000010413 sodium alginate Nutrition 0.000 claims description 6
229940005550 sodium alginate Drugs 0.000 claims description 6
CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 5
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 5
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
239000005977 Ethylene Substances 0.000 claims description 5
229930091371 Fructose Natural products 0.000 claims description 5
239000005715 Fructose Substances 0.000 claims description 5
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
229930195725 Mannitol Natural products 0.000 claims description 5
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 5
235000011187 glycerol Nutrition 0.000 claims description 5
239000008101 lactose Substances 0.000 claims description 5
239000000594 mannitol Substances 0.000 claims description 5
235000010355 mannitol Nutrition 0.000 claims description 5
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 5
239000001540 sodium lactate Substances 0.000 claims description 5
235000011088 sodium lactate Nutrition 0.000 claims description 5
229940005581 sodium lactate Drugs 0.000 claims description 5
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 5
239000000811 xylitol Substances 0.000 claims description 5
235000010447 xylitol Nutrition 0.000 claims description 5
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 5
229960002675 xylitol Drugs 0.000 claims description 5
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
229920001451 polypropylene glycol Polymers 0.000 claims description 4
239000007788 liquid Substances 0.000 claims description 3
238000003756 stirring Methods 0.000 claims description 3
239000004202 carbamide Substances 0.000 claims description 2
229920001184 polypeptide Polymers 0.000 claims description 2
102000004196 processed proteins & peptides Human genes 0.000 claims description 2
108090000765 processed proteins & peptides Proteins 0.000 claims description 2
238000004090 dissolution Methods 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 abstract description 8
230000035939 shock Effects 0.000 abstract description 8
235000017557 sodium bicarbonate Nutrition 0.000 abstract description 4
229910000030 sodium bicarbonate Inorganic materials 0.000 abstract description 4
238000004519 manufacturing process Methods 0.000 abstract description 2
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 abstract 1
159000000000 sodium salts Chemical class 0.000 abstract 1
210000004369 blood Anatomy 0.000 description 29
239000008280 blood Substances 0.000 description 29
238000001802 infusion Methods 0.000 description 20
229960001031 glucose Drugs 0.000 description 13
241000282472 Canis lupus familiaris Species 0.000 description 10
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
229940079593 drug Drugs 0.000 description 8
239000003814 drug Substances 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000000819 hypertonic solution Substances 0.000 description 6
229940021223 hypertonic solution Drugs 0.000 description 6
102000009027 Albumins Human genes 0.000 description 5
108010088751 Albumins Proteins 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
239000007983 Tris buffer Substances 0.000 description 4
230000000703 anti-shock Effects 0.000 description 4
230000036772 blood pressure Effects 0.000 description 4
239000007853 buffer solution Substances 0.000 description 4
239000000084 colloidal system Substances 0.000 description 4
239000013078 crystal Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000001914 filtration Methods 0.000 description 4
239000003058 plasma substitute Substances 0.000 description 4
238000003860 storage Methods 0.000 description 4
238000012360 testing method Methods 0.000 description 4
210000002700 urine Anatomy 0.000 description 4
208000001953 Hypotension Diseases 0.000 description 3
239000008156 Ringer's lactate solution Substances 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
230000000740 bleeding effect Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 3
229960002737 fructose Drugs 0.000 description 3
229960005150 glycerol Drugs 0.000 description 3
230000000004 hemodynamic effect Effects 0.000 description 3
230000036543 hypotension Effects 0.000 description 3
229960001375 lactose Drugs 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
238000002633 shock therapy Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
206010019280 Heart failures Diseases 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
206010037423 Pulmonary oedema Diseases 0.000 description 2
208000001647 Renal Insufficiency Diseases 0.000 description 2
206010039424 Salivary hypersecretion Diseases 0.000 description 2
FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
240000006394 Sorghum bicolor Species 0.000 description 2
235000011684 Sorghum saccharatum Nutrition 0.000 description 2
206010047700 Vomiting Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
239000010425 asbestos Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
235000011148 calcium chloride Nutrition 0.000 description 2
239000004227 calcium gluconate Substances 0.000 description 2
235000013927 calcium gluconate Nutrition 0.000 description 2
229960004494 calcium gluconate Drugs 0.000 description 2
MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
239000001527 calcium lactate Substances 0.000 description 2
235000011086 calcium lactate Nutrition 0.000 description 2
229960002401 calcium lactate Drugs 0.000 description 2
NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 2
230000009084 cardiovascular function Effects 0.000 description 2
210000000748 cardiovascular system Anatomy 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
230000006378 damage Effects 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
230000036039 immunity Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
201000006370 kidney failure Diseases 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000004089 microcirculation Effects 0.000 description 2
239000001103 potassium chloride Substances 0.000 description 2
235000011164 potassium chloride Nutrition 0.000 description 2
239000000047 product Substances 0.000 description 2
208000005333 pulmonary edema Diseases 0.000 description 2
229910052895 riebeckite Inorganic materials 0.000 description 2
208000026451 salivation Diseases 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
230000008961 swelling Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000008673 vomiting Effects 0.000 description 2
230000003313 weakening effect Effects 0.000 description 2
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
206010048962 Brain oedema Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
208000009366 Echinococcosis Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
208000004751 Hepatic Echinococcosis Diseases 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
208000005485 Thrombocytosis Diseases 0.000 description 1
206010044541 Traumatic shock Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
230000009471 action Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000702 anti-platelet effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
208000006752 brain edema Diseases 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
206010007625 cardiogenic shock Diseases 0.000 description 1
230000005792 cardiovascular activity Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000010411 cooking Methods 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
210000003191 femoral vein Anatomy 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
230000020764 fibrinolysis Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
238000001631 haemodialysis Methods 0.000 description 1
230000000322 hemodialysis Effects 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
206010019847 hepatosplenomegaly Diseases 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000035987 intoxication Effects 0.000 description 1
231100000566 intoxication Toxicity 0.000 description 1
210000002977 intracellular fluid Anatomy 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
238000002690 local anesthesia Methods 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000036284 oxygen consumption Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
230000002861 ventricular Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Inorganic Chemistry (AREA)
Organic Chemistry (AREA)
Dermatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Diabetes (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

UA2000116454A 1998-05-15 1999-04-16 Pharmaceutical composition for treatment of patients in intensive care units and method for its preparation UA72735C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CN98108902A CN1068778C (zh)	1998-05-15	1998-05-15	救治用的药物组合物及其制备方法
PCT/CN1999/000055 WO1999059602A1 (en)	1998-05-15	1999-04-16	Novel pharmaceutical composition for use in emergency treatment and preparation method thereof

Publications (1)

Publication Number	Publication Date
UA72735C2 true UA72735C2 (en)	2005-04-15

Family

ID=5219795

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2000116454A UA72735C2 (en)	1998-05-15	1999-04-16	Pharmaceutical composition for treatment of patients in intensive care units and method for its preparation

Country Status (20)

Country	Link
US (2)	US6986905B1 (de)
EP (1)	EP1078636B1 (de)
JP (1)	JP2002515441A (de)
KR (1)	KR20010043585A (de)
CN (1)	CN1068778C (de)
AP (1)	AP1185A (de)
AT (1)	ATE456954T1 (de)
AU (1)	AU754537B2 (de)
BR (1)	BR9911020A (de)
CA (1)	CA2332038C (de)
DE (1)	DE69941996D1 (de)
EA (1)	EA003369B1 (de)
IL (1)	IL139658A (de)
MX (1)	MXPA00011216A (de)
OA (1)	OA11553A (de)
PL (1)	PL196087B1 (de)
RO (1)	RO122394B1 (de)
TR (1)	TR200003315T2 (de)
UA (1)	UA72735C2 (de)
WO (1)	WO1999059602A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR9904471A (pt) *	1999-08-02	2001-03-13	Mateus Sommer Neto	Composção coloidal para correção estética
EP1398324A1 (de) *	2002-09-11	2004-03-17	Fuji Photo Film B.V.	Gelatin-artige Proteine als Plasma-Expander und als Plasmaersatz geeignete Verbindungen
US20080125488A1 (en) *	2003-05-01	2008-05-29	Leverve Xavier M	Lactate Containing Pharmaceutical Composition and Uses Thereof
US20060018852A1 (en)	2003-08-22	2006-01-26	L'oreal	Compositions containing topical active agents and pentylene glycol
US20050064045A1 (en) *	2003-09-18	2005-03-24	Sheng-Ping Zhong	Injectable therapeutic formulations
US7906125B2 (en)	2003-09-18	2011-03-15	Boston Scientific Scimed, Inc.	Solid or semi-solid therapeutic formulations
US7862552B2 (en)	2005-05-09	2011-01-04	Boston Scientific Scimed, Inc.	Medical devices for treating urological and uterine conditions
US8263109B2 (en)	2005-05-09	2012-09-11	Boston Scientific Scimed, Inc.	Injectable bulking compositions
CN100333728C (zh) *	2005-05-11	2007-08-29	中国人民解放军第二军医大学	一种复方电解质果糖注射液
CN100394924C (zh) *	2005-09-23	2008-06-18	赵超英	一种高渗液药物组合物在制备麻醉前使用的药物中的应用
CN101209344B (zh) *	2006-12-28	2012-07-04	赵超英	高渗液组合物在制备促进伤口愈合的药物中的应用
US8790714B2 (en) *	2007-08-03	2014-07-29	Nucitec, S.A. De C.V.	Compositions and methods for treatment and prevention of osteoarthritis
DE102007047040A1 (de) *	2007-10-01	2009-04-16	Fresenius Kabi Deutschland Gmbh	Transparentes Kältegel
CN101167740B (zh) *	2007-10-16	2010-05-19	中国大冢制药有限公司	复方醋酸钠电解质注射液及其制备方法
CN100544734C (zh) *	2007-10-16	2009-09-30	中国大冢制药有限公司	复方果糖电解质注射液及其制备方法
MD4117C1 (ro) *	2010-07-30	2012-02-29	Институт Химии Академии Наук Молдовы	Pudră cu capacitate hemostatică şi regenerativă (variante) şi procedeu de obţinere a acesteia
CN102000109B (zh) *	2010-09-30	2013-06-05	泰山医学院	基于氢为治疗物质的药物制剂及其制备方法
RU2471489C1 (ru) *	2011-12-22	2013-01-10	Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии Сибирского отделения РАМН (НИИ фармакологии СО РАМН)	Средства, повышающие выживаемость при травматическом шоке
CN103845358B (zh) *	2012-12-04	2015-11-25	江苏恒瑞医药股份有限公司	包含羟乙基淀粉和含有碳酸氢根离子的电解质溶液的药物组合物
PT2981258T (pt) *	2013-04-05	2020-10-19	Scpharmaceuticals Inc	Formulações farmacêuticas para administração subcutânea de furosemida
CN104644669A (zh) *	2013-11-19	2015-05-27	北大方正集团有限公司	一种急救用的代血浆药物组合物及其制备方法
CA3087953C (en)	2018-01-12	2025-11-25	Metimedi Pharmaceuticals Co., Ltd.	METHODS OF TREATMENT FOR CHRONIC INFLAMMATORY DISEASES
ES3041602T3 (en)	2018-12-10	2025-11-13	Sq Innovation Ag	Pharmaceutical compositions of furosemide and uses thereof
US12397005B2 (en)	2019-01-04	2025-08-26	Sq Innovation Ag	Pharmaceutical compositions of torsemide and uses thereof
US11246851B2 (en)	2019-01-04	2022-02-15	Sq Innovation Ag	Pharmaceutical compositions of furosemide and uses thereof
PH12021551811A1 (en)	2019-01-31	2022-03-21	Scpharmaceuticals Inc	Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
US12419850B1 (en)	2024-03-21	2025-09-23	GanD, Inc.	Bioactive fluid compositions
CN119868405A (zh) *	2024-12-31	2025-04-25	上海怿勤生物科技有限公司	一种基于果糖的复方电解质注射液及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5835485B2 (ja) *	1976-02-03	1983-08-03	株式会社ミドリ十字	酸素運搬輸液
US4908350A (en) *	1985-10-31	1990-03-13	The Regents Of The University Of California	Hyperosmotic/hyperoncotic solutions for resuscitation of hypodynamic shock
US4927806A (en) *	1987-04-23	1990-05-22	The Regents Of The University Of California	Saturated salt/concentrated dextran formulation to treat hemorrhage
CN1042474A (zh) *	1988-11-10	1990-05-30	济南军区药物研究中心	果胶代血浆及制备方法
US5292535A (en) *	1990-06-15	1994-03-08	Regents Of The University Of California	Hyperosmotic solutions for isonatremic resuscitation
JPH0469341A (ja) *	1990-07-05	1992-03-04	Otsuka Pharmaceut Factory Inc	Ｔｐｎ用糖電解質液
US5704297A (en) *	1991-02-06	1998-01-06	The Dupont Merck Pharmaceutical Company	Dry powder composition of hydroxyethyl starch suitable for reconstitution
US5248507A (en) *	1991-05-31	1993-09-28	Board Of Regents, The University Of Texas System	Hypertonic isochloremic formulation for circulatory shock
JPH06135852A (ja) *	1992-10-23	1994-05-17	Takada Seiyaku Kk	ウリナスタチン注射液
ES2157260T3 (es) *	1993-06-04	2001-08-16	Biotime Inc	Solucion semejante a plasma.
RU2056837C1 (ru) *	1995-03-22	1996-03-27	Государственный институт кровезаменителей и медицинских препаратов	Лекарственное средство "квинтасоль" для нормализации нарушений кислотно-щелочного равновесия и водно-электролитного баланса
GB9526741D0 (en) *	1995-12-30	1996-02-28	Sobering Thoughts Ltd	Product for combatting dehydration
WO1998008500A1 (en) *	1996-08-26	1998-03-05	Board Of Regents, The University Of Texas System	Hypertonic arginine compositions and methods
CN1156587A (zh) *	1996-12-13	1997-08-13	孙旭光	无晶甘露醇注射液及其制备方法
CN1195527A (zh) *	1997-04-07	1998-10-14	毕研文	低盐中分子羟乙基淀粉液

1998
- 1998-05-15 CN CN98108902A patent/CN1068778C/zh not_active Expired - Lifetime
1999
- 1999-04-16 WO PCT/CN1999/000055 patent/WO1999059602A1/zh not_active Ceased
- 1999-04-16 JP JP2000549266A patent/JP2002515441A/ja not_active Ceased
- 1999-04-16 CA CA002332038A patent/CA2332038C/en not_active Expired - Fee Related
- 1999-04-16 AP APAP/P/2000/002010A patent/AP1185A/en active
- 1999-04-16 TR TR2000/03315T patent/TR200003315T2/xx unknown
- 1999-04-16 AU AU35147/99A patent/AU754537B2/en not_active Ceased
- 1999-04-16 IL IL13965899A patent/IL139658A/en not_active IP Right Cessation
- 1999-04-16 BR BR9911020-2A patent/BR9911020A/pt not_active IP Right Cessation
- 1999-04-16 MX MXPA00011216A patent/MXPA00011216A/es active IP Right Grant
- 1999-04-16 EP EP99916742A patent/EP1078636B1/de not_active Expired - Lifetime
- 1999-04-16 OA OA1200000312A patent/OA11553A/en unknown
- 1999-04-16 RO ROA200001120A patent/RO122394B1/ro unknown
- 1999-04-16 UA UA2000116454A patent/UA72735C2/uk unknown
- 1999-04-16 DE DE69941996T patent/DE69941996D1/de not_active Expired - Fee Related
- 1999-04-16 PL PL344246A patent/PL196087B1/pl not_active IP Right Cessation
- 1999-04-16 AT AT99916742T patent/ATE456954T1/de not_active IP Right Cessation
- 1999-04-16 EA EA200001191A patent/EA003369B1/ru not_active IP Right Cessation
- 1999-04-16 KR KR1020007012724A patent/KR20010043585A/ko not_active Ceased
2000
- 2000-11-15 US US09/713,498 patent/US6986905B1/en not_active Expired - Fee Related
2005
- 2005-08-05 US US11/198,696 patent/US7309502B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
KR20010043585A (ko)	2001-05-25
US6986905B1 (en)	2006-01-17
TR200003315T2 (tr)	2001-06-21
WO1999059602A1 (en)	1999-11-25
PL196087B1 (pl)	2007-12-31
EP1078636A1 (de)	2001-02-28
IL139658A (en)	2005-12-18
EP1078636A4 (de)	2003-07-02
EA200001191A1 (ru)	2001-08-27
RO122394B1 (ro)	2009-05-29
AU3514799A (en)	1999-12-06
CA2332038A1 (en)	1999-11-25
AU754537B2 (en)	2002-11-21
AP1185A (en)	2003-07-04
JP2002515441A (ja)	2002-05-28
CN1068778C (zh)	2001-07-25
DE69941996D1 (de)	2010-03-25
IL139658A0 (en)	2002-02-10
AP2000002010A0 (en)	2000-12-31
HK1035146A1 (en)	2001-11-16
CN1235833A (zh)	1999-11-24
US20050288235A1 (en)	2005-12-29
MXPA00011216A (es)	2003-04-22
US7309502B2 (en)	2007-12-18
PL344246A1 (en)	2001-10-22
ATE456954T1 (de)	2010-02-15
EA003369B1 (ru)	2003-04-24
CA2332038C (en)	2009-01-27
EP1078636B1 (de)	2010-02-03
BR9911020A (pt)	2002-03-05
OA11553A (en)	2004-05-26

Publication	Publication Date	Title
UA72735C2 (en)	2005-04-15	Pharmaceutical composition for treatment of patients in intensive care units and method for its preparation
Margulis et al.	1989	Temporary organ substitution by hemoperfusion through suspension of active donor hepatocytes in a total complex of intensive therapy in patients with acute hepatic insufficiency
CA2045610C (en)	1996-03-12	Histidine buffered peritoneal dialysis solution
US20100136140A1 (en)	2010-06-03	A use of hypertonic solution composition in manufacturing medicaments for promoting wound healing
TW200301694A (en)	2003-07-16	Bicarbonate-based solutions for dialysis therapies
Farman et al.	1974	Liver transplantation in man: anaesthetic and biochemical management
ALTEMEIER et al.	1958	Nature and treatment of septic shock
King et al.	1969	Effect of intravenous injection of marihuana
Mullins et al.	1999	Life-threatening diphenhydramine overdose treated with charcoal hemoperfusion and hemodialysis
Closs et al.	1970	Methanol poisoning
Bocci et al.	2006	Ozone therapy in critical patients. Rationale of the therapy and proposed guidelines
JPH05507709A (ja)	1993-11-04	血中ナトリウム値無変化救急蘇生のための高張液
Michaud et al.	2001	Four percent trisodium citrate as an alternative anticoagulant for maintaining patency of central venous hemodialysis catheters: case report and discussion
RU2245150C1 (ru)	2005-01-27	Полифункциональный кровезаменитель
Bocci	2010	The Actual Six Therapeutic Modalities
HK1119580A (en)	2009-03-13	Use of high osmotic liquid composition in manufacturing medicament for enhancing wound healing
Kaufman et al.	1986	Sodium poisoning: a lethal case of a burned child
HK1035146B (en)	2010-05-07	Pharmaceutical composition for use in emergency treatment and preparation method thereof
RU2475234C2 (ru)	2013-02-20	Способ профилактики тяжелых осложнений при хирургическом лечении массивных и субмассивных кровопотерь с продолжающимся кровотечением
RU2382640C1 (ru)	2010-02-27	Способ лечения больных с гнойно-воспалительными заболеваниями нижних конечностей на фоне сахарного диабета
BINGSEN et al.	1991	Successful healing of a burn injury covering 100% of TBSA and 96% IIIrd degree with inhalation injury
CN119868405A (zh)	2025-04-25	一种基于果糖的复方电解质注射液及其制备方法